Endometrial Cancer Treatment Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2015 to 2020 and Forecast 2021 to 2027

$ PRICE - $ 3,000.00$ 8,900.00

Endometrial Cancer Treatment Market by Treatment (Chemotherapy, Radiation Therapy, Hormonal Therapy, Surgery), by Distribution Channel (Hospitals, Retail Pharmacies, Others) and Geography (North America, Latin America, Europe, Asia Pacific and Middle East and Africa)

 

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail

Report

Description

Endometrial cancer is the most common female genital cancer that begins in endometrium of the uterus. Signs and symptoms may include vaginal bleeding and pelvic pain. Usually diagnosed by the pelvic examination, ultrasound scanning and other techniques. Treatment may include, chemotherapy, radiation therapy or hormonal therapy. The report gives a comprehensive outlook on endometrial cancer treatment across the globe with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. The report gives historical, current, and future market sizes (US$ Mn) on the basis of treatment, distribution Channel and region. This report studies global endometrial cancer treatment market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, global market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed global endometrial cancer treatment market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product opportunities). Key stakeholders of the global market report include suppliers, manufacturers, marketers, policymakers, and healthcare service providers engaged in global endometrial cancer treatment products.In September 2019, the US FDA approved Merck’s anti-programmed cell death protein 1 (PD-1) Keytruda and Eisai’s kinase inhibitor Lenvima for certain advanced endometrial carcinoma patients. On May 30, 2019, AbilityPharma (Ability Pharmaceuticals, SL) released the first results of the currently ongoing phase 1/2a clinical trial evaluating ABTL0812 combined with carboplatin and paclitaxel in patients with endometrial cancer or non-small cell lung cancer. The results correspond to the phase 1 part of the Phase 1/2a clinical trial.


Endometrial Cancer Treatment Market

MARKET SUMMARY
-
x
  • Study Period– 2021 – 2027
  • Base Year– 2020
  • CAGR– x%
  • Largest Market– North America
  • Fastest Growing Market– Europe

Endometrial Cancer Treatment Market

  • Growing prevalence of the obesity in woman worldwide contribute majorly to the incidence of endometrial cancer. Companies in endometrial cancer treatment market are actively focused on development of new drugs and treatments for the treatment.
  • Furthermore, acquisitions and mergers also key strategies adopted by the market players to boost its market share. For instance, in August 2015, R-PHARM US has acquired IXEMPRA from Bristol-Mayer Squibb and started its commercial operations in U.S. Companies also expanding its presence and expanding the portfolio in various regions.
  • According to WHO, developed regions such as North America and Europe registers greater incidence rate for endometrial cancer due to lifestyle changes adopted by women.
Market Leaders
  • Abbott Laboratories (U.S.)
  • Becton, Dickinson and Company (U.S.)
  • Ariad Pharmaceuticals, Inc. (U.S.)
  • GlaxoSmithKline Plc (U.K.)
  • Hoffmann-La Roche AG (Switzerland)
  • Novartis AG (Switzerland)
  • Merck & Co., Inc. (U.S.)
  • Siemens Healthcare GmbH (Germany)
  • Sanofi (France)
Endometrial Cancer Treatment Market

Drivers and Restraints

Primary drivers for endometrial cancer treatment market include increase in the prevalence of endometrial cancer and increase in awareness and availability of minimally invasive treatments such as radiation therapy. According to American Cancer Society, in 2012, about 47,130 new cases of endometrial cases were diagnosed. In addition, increase in healthcare expenditure, technological advancements and developments and advanced healthcare services also propels the market growth of endometrial cancer treatment globally. In addition growing obesity in female population also one of the risk factor for growing prevalence of endometrial cancer worldwide. However, the side effects related to the chemotherapy, divergent nature of cancer and stringent regulatory requirements for the development of new treatments for the cancer are projected to hamper the market growth over the forecast period.


North America dominates the market

Endometrial Cancer Treatment Market

Geographically, global endometrial cancer treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America market is expected to have the significant market share globally owing the factors such as high incidence rates of uterine serous carcinoma and high healthcare expenditure. According to American Cancer Society, in 2017, about 61380 new cases of uterine cancer were diagnosed and around 10,000 were dead. Europe market expected to have the notable growth rate owing to high availability of the treatment options and products in treatment of endometrial cancer in the region. Asia Pacific market projected to have the gainful market opportunity over the forecast period due to growing economy, increase in healthcare expenditure and advancements in the cancer screening techniques backed by growing awareness.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Key Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2015-2020) and forecast (2021-2027)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Endometrial Cancer Treatment Market Segmentation


Location

GEOGRAPHY


Report

Table Of Content


Report

Company Profile

  • Abbott Laboratories (U.S.)
  • Becton, Dickinson and Company (U.S.)
  • Ariad Pharmaceuticals, Inc. (U.S.)
  • GlaxoSmithKline Plc (U.K.)
  • Hoffmann-La Roche AG (Switzerland)
  • Novartis AG (Switzerland)
  • Merck & Co., Inc. (U.S.)
  • Siemens Healthcare GmbH (Germany)
  • Sanofi (France)

Description

Endometrial cancer is the most common female genital cancer that begins in endometrium of the uterus. Signs and symptoms may include vaginal bleeding and pelvic pain. Usually diagnosed by the pelvic examination, ultrasound scanning and other techniques. Treatment may include, chemotherapy, radiation therapy or hormonal therapy. The report gives a comprehensive outlook on endometrial cancer treatment across the globe with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. The report gives historical, current, and future market sizes (US$ Mn) on the basis of treatment, distribution Channel and region. This report studies global endometrial cancer treatment market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, global market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed global endometrial cancer treatment market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product opportunities). Key stakeholders of the global market report include suppliers, manufacturers, marketers, policymakers, and healthcare service providers engaged in global endometrial cancer treatment products.In September 2019, the US FDA approved Merck’s anti-programmed cell death protein 1 (PD-1) Keytruda and Eisai’s kinase inhibitor Lenvima for certain advanced endometrial carcinoma patients. On May 30, 2019, AbilityPharma (Ability Pharmaceuticals, SL) released the first results of the currently ongoing phase 1/2a clinical trial evaluating ABTL0812 combined with carboplatin and paclitaxel in patients with endometrial cancer or non-small cell lung cancer. The results correspond to the phase 1 part of the Phase 1/2a clinical trial.

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX